# GPT 5.2 Review - Reviewer 2/3 (Parallel)

**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Reasoning effort:** medium
**Timestamp:** 2026-01-21T16:28:59.822752
**Review mode:** Parallel (3 independent reviewers)
**Response ID:** resp_03376896b8a8d453006970f01bc2b48197aa9f4a13a249f69c
**Tokens:** 10055 in / 5783 out
**Response SHA256:** d729a4e8b4a14ee3

---

## Referee Report: “Do State Insulin Price Caps Improve Diabetes Management? Evidence from Staggered Policy Adoption” (January 2026)

### Summary
The paper asks an important policy question—whether state insulin out-of-pocket (OOP) caps improve diabetes management—and uses BRFSS 2019–2022 with staggered DiD (Callaway–Sant’Anna; Sun–Abraham). The headline result is a small, imprecise increase in self-reported insulin use (+1.9pp, SE 1.3pp) and essentially zero effects on A1C monitoring; event studies show positive post coefficients but also statistically significant pre-trends.

The topic fits AEJ:EP / AER P&P–style policy evaluation, but in its current form it falls far short of the identification, measurement, and presentation standards for a top general-interest journal. The most serious issues are (i) outcomes and treatment are mismatched (caps apply to a subset of insured plans; the analysis averages across all diabetics), (ii) the short panel and COVID-era shocks make the design extremely fragile, and (iii) the event studies show statistically significant pre-trends that undermine the paper’s causal claims.

---

# 1. FORMAT CHECK

**Length**
- **Fails**: The manuscript shown is **~17 pages** (pages numbered 1–17 including appendix material). This is well below the **25+ page** norm for a top field/general journal main text (excluding references/appendix). Even if additional pages exist off-screen, the current draft reads like a short report rather than a journal article.

**References / coverage**
- **Fails**: References list contains **only 7 items** (p. 15) and the text contains multiple placeholder citations (“(?)”, “??”) throughout the Introduction and Background (pp. 2–4, 12–13). This is not acceptable for peer review. The bibliography does not adequately cover:
  - insulin pricing / affordability / rationing empirical literature,
  - state insulin cap policy evaluations (spending, access),
  - modern DiD event-study inference and pre-trend diagnostics,
  - inference with few treated clusters / staggered adoption.

**Prose vs bullets**
- **Mostly passes**: Sections are largely in paragraph form. Bullets are used mainly for variable definitions (p. 5) and interpretive lists (p. 12), which can be acceptable. However, the Discussion section’s structure (p. 12) reads like a memo with labeled bullet-style claims (“No effect.” “Small effect, masked…”) rather than a journal narrative.

**Section depth (3+ substantive paragraphs each)**
- **Mixed**:
  - Introduction (pp. 2–3): ~4 paragraphs → **pass**.
  - Institutional background (pp. 3–4): multiple paragraphs → **pass**.
  - Data (pp. 5–6): at least 3 paragraphs plus bullets → **borderline pass**.
  - Results (pp. 8–11): has subsections, but many claims are brief; the causal argument is not developed deeply → **borderline**.
  - Discussion/Conclusion (pp. 12–13): several short paragraphs, but not at the level of depth expected for AER/QJE/JPE → **fail for top-journal standard**.

**Figures**
- **Mixed**: Figures have axes and labels, but several appear low-resolution and not publication quality (e.g., Figure 1 and 3 in the provided images). Event study figure (p. 9) has axes and CI depiction—good. For a top journal, you need consistent formatting, legible fonts, and a clear explanation of construction and sample in the figure notes.

**Tables**
- **Pass**: Tables contain real numbers (Tables 2–4, pp. 6, 8, 11). However, Table 3 reports “State-years 78–212” (p. 8), which is ambiguous and not acceptable: each estimate must map to a clearly defined estimation sample and N.

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

### a) Standard Errors
- **Mostly passes**: Key coefficients in Tables 3–4 have SEs in parentheses (pp. 8, 11). Placebo and leave-one-out SE/CI appear in figures/text.
- **But**: Many reported quantities are not fully accompanied by inference in a table (e.g., dynamic/event-time coefficients are only graphed; no accompanying table with exact estimates and SEs).

### b) Significance testing
- **Borderline**: The paper states when things are “statistically significant” and provides SEs and 95% CIs for the main ATT (Abstract p.1; Table 3 p.8). However, **no p-values, no t-stats, and no conventional significance markers** appear in tables. Top journals do not require stars, but they do require **transparent inference reporting**; the current presentation is incomplete.

### c) Confidence intervals
- **Pass (main ATT)**: 95% CI is shown for main outcomes (Table 3, p. 8; Abstract p. 1). Event-study CIs are graphed.

### d) Sample sizes
- **Fails**: N is not reported consistently and precisely. The text claims 1.7M respondents and ~220k diabetic person-years (p. 5), but the regressions are on aggregated state-year cells and Table 3 reports “State-years 78–212” (p. 8), which is not interpretable. Each model must report:
  - number of states,
  - number of state-year observations actually used,
  - number of treated cohorts contributing to each event time,
  - (ideally) population weights / effective sample size given BRFSS weighting.

### e) DiD with staggered adoption
- **Pass on estimator choice**: You use Callaway–Sant’Anna and Sun–Abraham, and you explicitly acknowledge TWFE bias (pp. 7–8). This is the right direction.
- **However (major concern)**: Because you aggregate to state-year means with only 4 years, your identifying variation is extremely limited. With staggered adoption and only 2019–2022, many cohorts have **0–1 post periods** and **very few pre periods**. The event study is therefore fragile, and the pre-trend rejections are hard to interpret but devastating for credibility.

### f) RDD
- Not applicable.

**Bottom line on methodology**: While the paper is not “unpublishable” due to a missing SE problem (SEs exist), it **is not publishable** in a top journal because inference is incomplete (unclear N; no systematic reporting for dynamics) and, more importantly, the design is not credibly identified (see Section 3).

---

# 3. IDENTIFICATION STRATEGY

### Credibility
At present, identification is **not credible** as a causal evaluation of insulin caps’ effects on diabetes management.

1. **Parallel trends is violated in your own event study**  
   - Figure 2 (p. 9) shows statistically significant pre-treatment coefficients at **t−2 and t−3**. You correctly flag that this “casts doubt” on parallel trends (Abstract p.1; Results p.9), but you still frame estimates as “treatment effects” throughout. With those pre-trends, the ATT is not interpretable as causal without additional structure.

2. **Treatment is mismeasured / diluted** (first-order issue)  
   - State caps typically apply to **state-regulated fully insured plans** and exclude **self-insured ERISA plans**; uninsured are also not directly covered (p. 3–4). Your outcome is **self-reported insulin use among all diabetics** (p. 5). This creates severe attenuation and, worse, potential bias if the composition of plan types differs systematically across adopting states and over time.
   - A top-journal design would at minimum implement **exposure-adjusted DiD** (e.g., interact treatment with pre-policy share fully insured / ACA marketplace enrollment / small-group share) or a **triple-difference** using individual insurance type (if available) or external state-year plan composition.

3. **COVID-era confounding is not a footnote; it dominates 2019–2022**  
   - You acknowledge COVID disruptions (p. 2, p. 12), but with only four years, 2020–2021 is exactly when health utilization and survey composition shifted sharply and differentially across states. A top-journal referee will not accept “limited” as a limitation; it is central.

4. **Timing/implementation issues are ignored**  
   - Texas effective Sept 2021 (Table 1, p. 4). BRFSS is annual; coding “treated in 2021” effectively assigns partial-year treatment. You need a clear rule (e.g., first full calendar year) and robustness to alternative timing (treat as 2022).

5. **State-year aggregation is problematic**  
   - Aggregating BRFSS microdata to state-year means (p. 5) discards information, complicates inference (sampling error in each cell), and invites ecological interpretation problems. It also prevents micro-level controls and subgroup analyses that are essential given partial coverage of the policy.

### Placebos and robustness
- You include leave-one-out and a placebo (pp. 10–11). These are fine as descriptive checks, but they do not repair the identification failure from pre-trends and exposure dilution.
- Missing robustness that would be expected:
  - alternative control groups (never-treated only vs not-yet-treated),
  - cohort-specific trends or state-specific linear trends (with strong caution, but informative),
  - modern **pre-trend-adjusted** or **honest DiD** inference (Rambachan–Roth),
  - permutation/randomization inference on adoption timing (especially with few clusters).

### Conclusions vs evidence
- The Abstract and Conclusion (p.1, p.13) are relatively cautious, but still too close to causal language given the pre-trends. For a top journal, you must either (i) fix identification, or (ii) reframe as a descriptive correlational analysis and stop calling ATT a policy effect.

---

# 4. LITERATURE (missing references + BibTeX)

### Methodology (DiD/event study)
You cite Callaway–Sant’Anna, Goodman-Bacon, Sun–Abraham (p. 15). You are missing several now-standard references expected in a top-journal DiD paper:

1) **de Chaisemartin & D’Haultfoeuille** (TWFE pathologies; alternative estimators)  
Why: Complements Goodman-Bacon and motivates estimator choice; widely cited in top journals.
```bibtex
@article{deChaisemartinDHaultfoeuille2020,
  author  = {de Chaisemartin, Cl{\'e}ment and D'Haultf{\oe}uille, Xavier},
  title   = {Two-Way Fixed Effects Estimators with Heterogeneous Treatment Effects},
  journal = {American Economic Review},
  year    = {2020},
  volume  = {110},
  number  = {9},
  pages   = {2964--2996}
}
```

2) **Cameron & Miller** (cluster-robust inference; few clusters concerns)  
Why: Your unit is state; inference with ~50 clusters and only 4 years needs careful justification and possibly wild bootstrap.
```bibtex
@article{CameronMiller2015,
  author  = {Cameron, A. Colin and Miller, Douglas L.},
  title   = {A Practitioner's Guide to Cluster-Robust Inference},
  journal = {Journal of Human Resources},
  year    = {2015},
  volume  = {50},
  number  = {2},
  pages   = {317--372}
}
```

3) **Rambachan & Roth** (“Honest DiD” / sensitivity to pre-trends)  
Why: Your pre-trends are statistically significant; you need sensitivity analysis rather than simply disclaiming.
```bibtex
@article{RambachanRoth2023,
  author  = {Rambachan, Ashesh and Roth, Jonathan},
  title   = {A More Credible Approach to Parallel Trends},
  journal = {Review of Economic Studies},
  year    = {2023},
  volume  = {90},
  number  = {5},
  pages   = {2555--2591}
}
```

4) (Optional but helpful) **Abadie et al.** synthetic control  
Why: With state policies and few periods, synthetic control / generalized synthetic control may be more appropriate.
```bibtex
@article{AbadieDiamondHainmueller2010,
  author  = {Abadie, Alberto and Diamond, Alexis and Hainmueller, Jens},
  title   = {Synthetic Control Methods for Comparative Case Studies: Estimating the Effect of California's Tobacco Control Program},
  journal = {Journal of the American Statistical Association},
  year    = {2010},
  volume  = {105},
  number  = {490},
  pages   = {493--505}
}
```

### Policy/health economics literature (insulin affordability, adherence, cost-sharing)
The domain literature is far too thin. At minimum, a top-journal paper needs to engage:
- the broader cost-sharing/adherence literature (beyond Chandra-Gruber-McKnight),
- insulin-specific affordability and rationing evidence (beyond Herkert et al.),
- any existing evaluations of state insulin caps (claims-based; insurer reports; Health Affairs/JAMA network work).

A safe, foundational addition is the RAND Health Insurance Experiment:
```bibtex
@article{ManningEtAl1987,
  author  = {Manning, Willard G. and Newhouse, Joseph P. and Duan, Naihua and Keeler, Emmett B. and Leibowitz, Arleen},
  title   = {Health Insurance and the Demand for Medical Care: Evidence from a Randomized Experiment},
  journal = {American Economic Review},
  year    = {1987},
  volume  = {77},
  number  = {3},
  pages   = {251--277}
}
```

**Important**: The paper currently includes placeholders “(?)” for key factual claims about insulin price growth and rationing deaths (pp. 2–3). Those must be replaced with authoritative citations (peer-reviewed or high-quality institutional sources).

---

# 5. WRITING QUALITY (CRITICAL)

### Prose vs bullets
- **Borderline fail for top journal**: While much is paragraph-form, the paper reads like an internal policy memo. Sections 6–7 (pp. 12–13) lean on enumerated interpretations rather than building a disciplined argument tied to identification.

### Narrative flow
- Motivation is clear (p. 2), but the paper does not deliver a compelling arc because the central empirical punchline is: “we can’t identify the effect; pre-trends violate assumptions.” That can still be publishable if the paper *then* pivots to a credible alternative design or a sharp bounding/sensitivity exercise. It doesn’t.

### Sentence quality and accessibility
- Generally readable and not overly technical; good job explaining TWFE concerns and why CS is used (pp. 7–8).
- However, many important statements are unsupported (“not obviously responses…” p. 4; “relatively clean pre-IRA window…” p. 4) and need evidence and/or careful caveats.

### Figures/tables quality
- Needs a full upgrade for publication: consistent style, legible fonts, clear reporting of sample sizes contributing to each event time, and explicit notes on weighting and clustering.

---

# 6. CONSTRUCTIVE SUGGESTIONS (how to make this publishable)

To have a shot at AEJ:EP (let alone AER/QJE/JPE), you likely need **new measurement and a redesigned empirical strategy**, not incremental edits.

## A. Fix the treatment–exposure mismatch (highest priority)
1) **Triple-difference / exposure-adjusted DiD**
   - Use variation in who is actually covered by caps:
     - state-year share in fully insured vs self-insured plans (from MEPS-IC, KFF, CPS/ACS imputations, or DOL/EBRI sources),
     - ACA marketplace enrollment share,
     - baseline prevalence of high-deductible plans.
   - Estimand: effect of caps *scaled by exposure*; report ITT and TOT-style estimates.

2) **Subgroup analysis**
   - If microdata allow: privately insured vs Medicaid vs uninsured; income groups; high cost-burden populations.
   - Your current all-diabetic average is almost designed to find nulls.

## B. Use outcomes that match the mechanism
BRFSS “Are you now taking insulin?” is a blunt binary measure (p. 5).
- If you remain in BRFSS, consider outcomes closer to access problems: cost-related medication nonadherence (if available), inability to see a doctor due to cost, etc. (Even these are imperfect.)
- Preferably move to **claims/EHR outcomes**:
  - pharmacy fills, days supply, adherence (PDC/MPR),
  - OOP spending distribution,
  - acute complications: DKA ED visits/hospitalizations, severe hyperglycemia, avoidable admissions.

## C. Repair identification and inference
1) **Honest/sensitivity DiD**
   - Implement Rambachan–Roth bounds given the pre-trends. This would turn the current “identification concern” into a quantitative statement: “Under plausible deviations from parallel trends, the effect lies in [a,b].”

2) **Randomization/permutation inference**
   - With state-level adoption timing and few periods, consider permutation tests reassigning adoption years to states to assess whether your estimated “effects” are unusual.

3) **Correct timing**
   - Recode treatment as first *full* year of policy exposure; show robustness for Texas and other mid-year implementations.

4) **Stop aggregating (if possible)**
   - Run CS DiD on individual microdata with BRFSS weights and cluster at state. At minimum, incorporate cell-level sampling error if you insist on aggregation.

## D. Reframe contribution honestly
If you cannot fix pre-trends and exposure:
- Reframe as: “Survey-based state-panel evidence is not informative / unreliable for detecting health impacts of insulin caps; here is why; here are power calculations; here is what data would be sufficient.”  
That could be valuable, but it is a different paper and likely not a top general-interest main article.

---

# 7. OVERALL ASSESSMENT

### Key strengths
- Important policy question with high public relevance.
- Correct awareness of staggered DiD pitfalls and use of modern estimators (pp. 7–9).
- Transparently reports pre-trend problems rather than hiding them (Abstract p.1; Figure 2 p.9).

### Critical weaknesses (publication blocking)
1) **Causal identification fails** due to statistically significant pre-trends (p. 9) and inadequate strategy to address them.
2) **Treatment is not aligned with the population measured** (caps apply to a subset of insured plans; outcome is all diabetics), generating severe dilution and potential bias.
3) **Data window is too short and dominated by COVID-era shocks** (2019–2022), making dynamic/event-study claims extremely fragile.
4) **Scholarly presentation is not top-journal ready**: under-length (~17 pages), placeholder citations, extremely thin references, ambiguous N reporting.

### Specific, actionable improvements
- Add exposure-adjusted/triple-diff design; move to claims/EHR; implement honest DiD sensitivity; fix timing; overhaul references; report N cleanly for every estimate and event time.

---

DECISION: REJECT AND RESUBMIT